Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST).
M. von Mehren
Consultant or Advisory Role - Novartis
Honoraria - Novartis
M. C. Heinrich
Consultant or Advisory Role - MolecularMD
Stock Ownership - MolecularMD
Research Funding - Arog; ImClone Systems; Novartis
Expert Testimony - MolecularMD
H. Joensuu
Consultant or Advisory Role - Novartis
Honoraria - Novartis
C. D. Blanke
Consultant or Advisory Role - Novartis
Honoraria - Novartis
E. Wehrle
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
G. D. Demetri
Consultant or Advisory Role - Alnylam; Amgen; ARIAD; ArQule; Bayer; Champions Biotechnology; Daiichi Sankyo; EMD Serono; Enzon; Genentech; GlaxoSmithKline; Idera; Infinity; Johnson & Johnson; Kolltan Pharmaceuticals; N-of-One (U); Novartis; Pfizer; Plexxikon; Takeda; ZIOPHARM Oncology
Stock Ownership - Champions Biotechnology; Kolltan Pharmaceuticals; N-of-One ; Plexxikon
Honoraria - Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; Daiichi Sankyo; Infinity; Johnson & Johnson; Novartis; Pfizer
Expert Testimony - ARIAD (U); Bayer (U); Infinity (U); Merck (U); Novartis (U); Pfizer (U)